Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-053699
Filing Date
2025-04-14
Accepted
2025-04-14 16:03:19
Documents
16
Period of Report
2025-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A kytx-20250414.htm   iXBRL DEF 14A 971203
2 GRAPHIC img189403811_0.jpg GRAPHIC 4502
3 GRAPHIC img189403811_1.jpg GRAPHIC 4502
4 GRAPHIC img189403811_2.jpg GRAPHIC 479563
5 GRAPHIC img189403811_3.jpg GRAPHIC 227261
  Complete submission text file 0000950170-25-053699.txt   2861454

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20250414.xsd EX-101.SCH 8685
18 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20250414_htm.xml XML 6591
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41947 | Film No.: 25836029
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)